Eli Lilly Board Member Trades $229K In Company Stock

Disclosed in the latest SEC filing, a significant insider purchase on November 20, involves Kimberly H Johnson, Board Member at Eli Lilly LLY.

What Happened: Johnson's recent purchase of 315 shares of Eli Lilly, disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday, reflects confidence in the company's potential. The total transaction value is $229,666.

As of Thursday morning, Eli Lilly shares are down by 1.56%, currently priced at $741.66.

Unveiling the Story Behind Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly's Economic Impact: An Analysis

Revenue Growth: Eli Lilly displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 20.43%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Key Profitability Indicators:

• Gross Margin: The company excels with a remarkable gross margin of 81.02%, indicating superior cost efficiency and profitability compared to its industry peers.

• Earnings per Share (EPS): Eli Lilly's EPS is below the industry average. The company faced challenges with a current EPS of 1.08. This suggests a potential decline in earnings.

Debt Management: Eli Lilly's debt-to-equity ratio surpasses industry norms, standing at 2.19. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Analyzing Market Valuation:

• Price to Earnings (P/E) Ratio: Eli Lilly's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 81.19.

• Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 16.67 suggests overvaluation in the eyes of investors, considering sales performance.

• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Eli Lilly's EV/EBITDA ratio of 59.36 exceeds industry averages, indicating a premium valuation in the market

Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

Illuminating the Importance of Insider Transactions

Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.

From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.

A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.

While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.

Important Transaction Codes

In the domain of transactions, investors frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Eli Lilly's Insider Trades.

Insider Buying Alert: Profit from C-Suite Moves

Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.

This article was generated by Benzinga's automated content engine and reviewed by an editor.